4LN2.F CAPRICOR THERAP. DL-001
- Market cap
- EUR 479M
- P/E
- -
- P/B
- 2.26x
- ROE
- -74.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4LN2.F undervalued?
Graham numberThe Graham number of CAPRICOR THERAP. DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CAPRICOR THERAP. DL-001 fundamental analysis
No fundamental analysis for CAPRICOR THERAP. DL-001 yet.
CAPRICOR THERAP. DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CAPRICOR THERAP. DL-001
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is i…
Full company profileCAPRICOR THERAP. DL-001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CAPRICOR THERAP. DL-001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 245K | 2.55M | 25.2M | 22.3M | 0.00 | 0.00 |
| Operating Income | -20.9M | -29.7M | -24.1M | -42.6M | -108M | -166M |
| EBITDA | - | -29.2M | -23.0M | -39.0M | -100M | -163M |
| Net Income | -20.0M | -29.0M | -22.3M | -40.5M | -105M | -156M |
| EPS | -0.83 | -1.15 | -0.72 | -0.89 | -1.83 | -2.69 |
| Balance Sheet | ||||||
| Total Assets | 41.3M | 50.1M | 58.7M | 170M | 356M | 330M |
| Total Liabilities | 9.96M | 38.3M | 36.1M | 25.0M | 50.2M | 121M |
| Shareholders' Equity | 31.4M | 11.8M | 22.6M | 145M | 306M | 210M |
| Cash & Short-term Investments | 34.9M | 9.60M | 14.7M | 11.3M | 288M | 44.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -16.8M | 4.92M | -25.6M | -40.0M | -69.8M | -129M |
| Capital Expenditure | 1.20M | 3.36M | 2.05M | 1.54M | 11.7M | 28.2M |
| Free Cash Flow | -18.0M | 1.56M | -27.6M | -41.5M | -81.5M | -157M |
| Ratios | ||||||
| ROE | -63.8% | -246.2% | -98.6% | -27.8% | -34.4% | -74.6% |
| ROA | -48.4% | -57.9% | -37.9% | -23.7% | -29.5% | -47.4% |
| Net Profit Margin | -8,175.9% | -1,137.4% | -88.5% | -181.7% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CAPRICOR THERAP. DL-001 dividends
CAPRICOR THERAP. DL-001 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Jun 5, 2019.
Who owns CAPRICOR THERAP. DL-001
- Insiders 9.44%
- Institutions 74.53%
- Public & others 16.04%
- Shares outstanding 58.1M
- Free float 45.5M
CAPRICOR THERAP. DL-001 company profile
- Company name
- CAPRICOR THERAP. DL-001
- Ticker
- 4LN2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 231
- Fiscal year end
- December
- Address
- 10865 Road to the Cure, San Diego, CA, United States, 92121
- Phone
- 858 727 1755
- Website
- capricor.com
About CAPRICOR THERAP. DL-001
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
CAPRICOR THERAP. DL-001 management
10- Dr. Frank Isaac Litvack FACC, M.D.Executive Chairman of the Board · born 1956
- Dr. Linda Marbán Ph.D.Co-Founder, President, CEO & Director · born 1963
- Mr. Anthony J. Bergmann M.B.A.CFO & Corporate Treasurer · born 1986
- Ms. Karen G. Krasney Esq., J.D.Executive VP, General Counsel & Secretary · born 1953
- Dr. Kristi A. H. Elliott Ph.D.Chief Operating & Science Officer
- Mr. Minghao Sun Ph.D.Senior Vice President of Quality Control, Research & Product Development
- Mr. Mark AwadallaChief Development Officer
- Dr. Micheal Binks M.D.Chief Medical Officer
- Mr. Michael MaurerChief Commercial Officer
- Nathaniel Hogan Ph.D.Director of Biostatistics of Capricor Therapeutics